Related Experiment Video

Updated: Feb 20, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.8K

Let-7a inhibits migration, invasion and tumor growth by targeting AKT2 in papillary thyroid carcinoma

Bin Zhou1, Hailin Shan1, Ying Su1

  • 1Department of Thyroid and Breast Surgery, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, China.

Oncotarget
|October 21, 2017
PubMed

Insights

MicroRNA let-7a is downregulated in papillary thyroid carcinoma (PTC), suppressing tumor growth. Targeting AKT2, let-7a shows potential for new PTC therapies.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Papillary thyroid carcinoma (PTC) is the most prevalent endocrine malignancy.
  • MicroRNAs (miRNAs) are increasingly recognized for their roles in PTC development and progression.

Purpose of the Study:

  • To investigate the role of let-7a in papillary thyroid carcinoma.
  • To identify the molecular targets of let-7a in PTC.
  • To explore let-7a as a potential therapeutic target for PTC.

Main Methods:

  • Quantitative real-time PCR to measure let-7a and AKT2 expression in PTC tissues and cell lines.
  • Cell proliferation, migration, and invasion assays to assess the functional impact of let-7a.
  • Western blotting to confirm AKT2 as a direct target of let-7a.

Main Results:

  • let-7a expression was significantly downregulated in PTC tissues and cell lines.
  • Overexpression of let-7a inhibited PTC cell proliferation, migration, and invasion.
  • AKT2 was identified as a direct target of let-7a, with inverse correlation in expression levels.
  • Increased AKT2 expression partially rescued the suppressive effects of let-7a.

Conclusions:

  • let-7a functions as a tumor suppressor in papillary thyroid carcinoma by targeting AKT2.
  • let-7a represents a potential therapeutic candidate for papillary thyroid carcinoma treatment.
Keywords:
AKT2let-7apapillary thyroid carcinomatumor growth

More Related Videos

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.7K
Induction and Analysis of Epithelial to Mesenchymal Transition10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

36.6K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K